Gland Pharma Ltd

Gland Pharma Limited announced that its board approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. ("Gland US") from Gland Pharma International Pte. Ltd., for a cash consideration of USD 5,001,208. The acquisition, expected to be completed by October 31, 2026, will make Gland US a direct wholly-owned subsidiary of Gland Pharma Limited, streamlining the corporate structure and removing multiple layers. Gland US, incorporated in March 2022, is involved in the marketing and distribution of pharmaceutical products and had a turnover of USD 87,342 for the fiscal year ending March 31, 2025, and USD 4,83,808 for the fiscal year ending March 31, 2024.

Gland Pharma Limited announced that its board approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd., for a cash consideration of USD 5,001,208. The acquisition, expected to be completed by October 31, 2026, will make Gland US a direct wholly-owned subsidiary of Gland Pharma Limited, streamlining the corporate structure and removing multiple layers. Gland Pharma USA Inc., incorporated on March 7, 2022, is involved in the marketing and distribution of pharmaceutical products and had a turnover of USD 87,342 for the fiscal year ending March 31, 2025, and USD 4,83,808 for the fiscal year ending March 31, 2024.

Gland Pharma Limited announced the allotment of 42,393 equity shares to 35 employees and 1,800 equity shares to one employee on September 13, 2026, following the exercise of stock options under the Gland Pharma Employee Stock Options Scheme, 2025 and Gland Pharma Limited Employee Stock Options Scheme, 2019. The company's board also approved the formal closure of the Gland Pharma Limited Employee Stock Option Scheme, 2019, resulting in an increase in the issued, subscribed, and paid-up share capital to Rs 16,50,10,854, comprising 165,010,854 equity shares.

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 2974.6, up 1.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.61% on the day, quoting at 23752.75. The Sensex is at 75996.71, down 0.68%. Gland Pharma Ltd has added around 11.52% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 0.31% in last one month and is currently quoting at 26478.1, up 0.32% on the day. The volume in the stock stood at 6.85 lakh shares today, compared to the daily average of 9.69 lakh shares in last one month.The PE of the stock is 34.25 based on TTM earnings ending June 26.

Gland Pharma Limited announced the appointment of Mr. Deepak Sapra as the new Chief Executive Officer (CEO), subject to his acceptance of the offer, with an effective date of November 16, 2026. Mr. Sapra, who currently serves as Chief Executive Officer – API and Services at Dr. Reddy’s Laboratories Limited and a Board Member of Aurigene Pharma Services, brings 27 years of executive experience, including over 23 years in the pharmaceutical industry.

Gland Pharma Ltd share price slipped 0.65% to Rs 2600.45 after the company's net profit contracted by 13.56% to Rs 316.96 crore, while revenue from operations improved marginally 3.30% to Rs 1800.27 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, gaining 5.15%. It has inched up 0.74% over last one week and advanced by 13.39% in last one month while the market capitalization of Gland Pharma Ltd has marginally improved by 0.90% and 39.08% in the same period respectively. Profit before tax (PBT) of Gland Pharma Ltd stood at Rs 434.98 crore in Q2 FY26, surging by 39.09% year-on-year, and dropping 14.00% quarter-on-quarter. EBITDA came in at Rs 428 crore, expanding by 38.01% YoY and easing 6.62% sequentially. Total expenses grew marginally by 6.26% to Rs 1422.16 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 588.2 crore, slightly declining by 0.99% YoY, while employee benefits expense was at Rs 444.0 crore, registering a growth of 7.88% YoY. For the TTM ended FY26, revenue from operations advanced 14.50% to Rs 6430.65 crore, while net profit surged by 47.07% to Rs 1027.32 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 110011% to Rs 1313.22 crore, and PBT soared 37.82% to Rs 1464.58 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1031.39 crore in FY26, as against Rs 914.73 crore in FY25. Gland Pharma Ltd jumped 32.87% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.

Gland Pharma Limited and Neuland Laboratories Limited announced a long-term strategic contract development and manufacturing organization (CDMO) partnership, under which Gland Pharma will establish a sterile manufacturing suite at its JNPC facility in Visakhapatnam to support Neuland’s demand for sterile APIs, with the suite designed to add approximately 1400 kg of annual capacity.

An independent audit verified a company’s Business Responsibility and Sustainability Report (BRSR), revealing key environmental, social, and governance (ESG) performance indicators. The report, assessed across multiple sites including Hyderabad, Dundigal, Pashamylaram, and JNPC, indicated a total waste generation of 3,223.79 metric tons, with a substantial 2,087.62 MT classified as “Other Hazardous Waste,” prompting a need for further review. While the company reports zero work-related injuries and fatalities, only 8.36% of total wages are paid to female employees, highlighting a potential area for improvement in gender diversity. The report also noted that all two Prevention of Sexual Harassment (POSH) complaints filed were upheld, suggesting a need to strengthen preventative measures. Purchases are heavily concentrated among a few trading houses and dealers, representing a potential supply chain risk.

Gland Pharma Limited announced that its ESOP Compensation Committee has allotted 6,979 equity shares of Re. 1/- each to 8 employees on the exercise of stock options under the Gland Pharma Employee Stock Options Scheme, 2025. Consequently, the company's issued, subscribed, and paid-up share capital increased to Rs 164,966,661, comprising 164,966,661 equity shares of Re. 1/- each.

Three employees were granted 16,790 options under the ESOP 2025 scheme on July 30, 2026, as announced by the company’s Board of Directors. The options, administered by the ESOP Compensation Committee, comply with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. A portion of the options, 11,081, were granted at an exercise price of INR 1258.50, which represents 50% of the NSE closing price on the grant date, while 5,709 options were granted at the face value of INR 1 per share. The vesting schedule is tiered, with 34% vesting after one year, 33% after two years, and the remaining 33% after three years, with a two-year exercise period following each vesting date. To date, no shares have been issued or realized from the exercise of these options, and there have been no variations or cancellations to the scheme.